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Abstract

Colorectal Cancer is the third most common cancer in men and women and the second
leading cause of cancer related deaths (ACS, 2019). Colonoscopy screening can prevent colon
cancer by early detection and removal of adenomatous colon polyps. The ACS has been lowered
from age 50 to 45 due to an increase in the prevalence of colon cancer in people below the age of
50 years of age. Molecular genetic screening is a tool that providers can use to identify patients
who are at risk for premature adenomas. People who have a genetic variant are more likely to
develop adenomas at a young age and have a faster adenoma to adenocarcinoma conversions
time. The purpose of this study is to identify if hereditary genetic screening has a positive or
negative predictive value on patients who present below the screening age and have the presence
of adenomas on a colonoscopy. This is a prospective study evaluated if a hereditary cancer
screening assessment was a viable tool to identify patients who were at risk for early adenomas.
A total of 150 charts were reviewed. The mean age of the participants was 40 years old, gender
distribution (39.3%) female and (60.7%) male, average BMI was 32.85, with 76.7% nonsmokers and 23% smokers. There was no statistically significant relationship found between
patients who answered positive for a personal family history of colon cancer, first degree family
history, and extended family history. There was a statistically significant correlation with
patients who answered positive to a second-degree family history. Limitations of the study
include small sample size, Participant recall or knowledge of family history and accuracy of the
genetic screening process. Doctorally Prepared Nurses serve as leader working at the top of their
education doing research to improve patient care outcomes. Nurse practitioners are a vital
member of the healthcare team.

SCHOLARLY PROJECT

5
TABLE OF CONTENTS

Chapter
1. INTRODUCTION………………………………………………………………… 9

2.

Empirical Evidence of Prevalence and Significance of Colon Cancer

9

Recommendations for Colonoscopy Screening

9

Risk Factors attributed to Colon Cancer

10

Changes in Screening age by the American Cancer Society

10

Purpose of Molecular Screening and Hereditary Cancer Screening

12

Clinical Question

15

PICO Question

16

Concepts and Definition of Terms

16

Theoretical Framework (Figure 1)

18

REVIEW OF LITERATURE ……………………………………………………. 22
Society Guidelines for Colonoscopy Screening

22

Society Recommendations for Evaluation of Lynch Syndrome

23

Colon Cancer Incidence Rates and Adenoma to Carcinoid Progression

24

Rates
Frequency and Prevalence of Colon Adenomas in Patients with Genetic

25

Variants
Barriers to Biomolecular Genetic Testing

26

SCHOLARLY PROJECT
Colorectal Cancer Screening for Average-risk Adults: 2018 Guideline

6
27

update from the American Cancer Society
American Gastroenterology Lynch Syndrome Management

27

Barriers to Research

28

3. METHODOLOGY………………………………………………………………… 30
Purpose Statement

30

Objective

30

Design

31

Procedure

31

Description of Measures

32

Protection of Human Subjects

33

Evaluation Plan

34

4. ANALYSIS OF RESULTS ………………………………………………………. 35
Description of Sample population

35

Hereditary Genetic Screening Survey

35

Pathology

35

Research Problem

36

Analysis of Project Question

36

Personal History of Hereditary Cancer and Adenoma Detection

36

First Degree Family History of Hereditary Cancer and Adenoma

37

Detection
Second Degree Family History of Hereditary Cancer and Adenomas
Detection

37

SCHOLARLY PROJECT

7

Extended Family History of Hereditary Cancer and Adenoma Detection

37

Additional Statistical Analysis

38

Gender
Smoking
Prevalence Rates
Unintended Consequences
Summary
5. DISCUSSION OF FINDINGS ………………………………………………….

39
41

Relationship of Outcomes to Research

41

Observations

41

Limitations

42

Implications for future research

42

Implications for practice/health policy/education

43

Conclusion

44

6. REFERENCES……………………………………………………………………. 46
7. APPENDICES……………………………………………………………………. 52
Appendix A Hereditary Cancer Screening Questionnaire

52

Appendix B IRB Approval

53

Appendix C Letter to Senator

54

Appendix D Student Learning Outcomes

55

Appendix E Essentials of Practice

60

Appendix F Data trends in CRC by age and birth year

65

Appendix G SPSS Data

6

SCHOLARLY PROJECT

8

CHAPTER 1
INTRODUCTION
Empirical Evidence of Prevalence and Significance of Colon Cancer
Colorectal cancer is the third most common cancer in men and women in the United
States (American Cancer Society, 2017). It is the second leading cause of cancer death in the
United States (JAMA, 2016). In 2015, 140,788 new cases of colorectal cancer (CRC) were
reported, and 52,396 people died from colorectal cancer (CDC, 2017). The age adjusted rate of
new colorectal cancer was 39.7 per 100,000 people (95% Confidence Interval: 38.3- 42.2); from
a total of 3,206 reported cases of colorectal cancer. The survival rate of all types of cancer is
65.6%, with colon cancer having a 5-year survival rate of 65.9% making the prediction and
screening of high-risk patients a vital issue to address in medicine. Incidence and death rates that
have been recorded by the United States Cancer Statistics identify a need for increased
awareness and screening protocols. One of the most disturbing developments in trends with
colon cancer is the marked increase in the incidence and mortality in the younger population who
are not of age to undergo colonoscopy screening. Data show that there was a sharp rise in the
1990’s that increased the incidence of colon cancer in Americans under the age of 50 years of
age with no epidemiological evidence explaining a cause.
The purpose of this study was to evaluate if hereditary cancer screening is appropriate to
initiate in the clinic setting as a valid screening tool to identify patients at greater risk for early
development of colorectal cancer or colon adenomas. Empirical evidence and research will be
taken from peer reviewed articles and professional medical associations.

SCHOLARLY PROJECT

9

Recommendations for Colonoscopy Screening
The American Cancer Society (ACS) recently changed their recommendations to begin
colonoscopy screening on average risk patients to 45 years of age, continuing until the age of 75
years old. Between the ages of 76 and 85 years the decision for colonoscopy should be based on
the individual’s state of health, life expectancy, and prior colonoscopy screenings. After the age
of 85, patients should not need colonoscopy screening.
Colonoscopy remains the gold standard for the detection and removal of colorectal
polyps. Other test modalities that may be used are annual high-sensitivity fecal occult blood test,
annual Cologuard test, flexible sigmoidoscopy every 5 years, or CT colonography every 5 years.
If any of these tests are positive, colonoscopy would be indicated and would no longer be
considered a screening exam which is covered 100% by insurance but would default to a
diagnostic colonoscopy which would be subject to the individual’s deductible. The decision for
what type of screening should be individualized and discussed with the patient.
There are currently two different organizations that regulate when insurance companies
will pay for a colonoscopy screening. The U.S. Preventive Task Force (USPTF) recommends
screening for colorectal cancer beginning at 50 years of age and continuing until age 75 years of
age. The decision to screen for colorectal cancer should be individualized and based on the
patient’s current state of health and previous colonoscopies (USPTF Colon Cancer Screening,
2016). Colonoscopy screening reduces colorectal cancer mortality (JAMA, 2016). Potential
adverse events associated with colonoscopy screening are rare however, increase with age. The
USPSTF states that with the with high certainty of colonoscopy the benefit outweighs the harm
(USPTF, 2016)
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State laws determine whether insurance companies will honor colonoscopy screening to
begin at age 45 per ACS guidelines or age 50 per USPTF guidelines. Tennessee follows ACS
guidelines (CRC Screening Law: State of Tennessee, 2019). Populations who are excluded from
screening colonoscopy include: a strong family history of colorectal cancer, a personal history of
colorectal cancer or colon adenomas, a personal history of inflammatory bowel disease, a known
family or personal history of genetically associated cancer syndrome such as familial
adenomatous polyposis syndrome also known as Lynch syndrome or hereditary non-polyposis
colon cancer (HNPCC); a personal history of radiation to the abdomen or pelvis to treat a prior
cancer (ACS, 2019). Reasons for these exclusions are that this population has already been
targeted as being high risk and American Gastroenterology Association and American Cancer
Society have published specific guidelines for this group of patients.
Risk Factors
Many risk factors have been associated with the development of colon cancer. Patients
who smoke, have a greater than normal BMI, consume high amounts of alcohol, decreased
dietary fiber, sedentary lifestyle, diet high in red meat and low in fruits and vegetables are at
increased risk for colon cancer (CDC, 2019). Patient who have certain medical conditions such
as inflammatory bowel disease (Crohns Disease, Ulcerative Colitis), or a history of abdominal or
pelvic radiation are at increased risk. Individuals who have a primary family history of colon
cancer or adenomatous colon polyps also have increased risk. All these factors are taken into
consideration when providers discuss colonoscopy screening with patients.
Changes in Screening Age by the American Cancer Society
The state of Tennessee and many other states set their screening protocols by the
recommendations of the American Cancer Society. The ACS bases its guidelines on trends noted
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over time periods. The ACS has recently lowered the screening age of average risk individuals
to begin at age 45 years old due to the increase in incidence rates of colon adenomas in the
middle age population. According to an observational study performed by Sigel et al. (2017),
taken from data recorded by the Surveillance, Epidemiology, and End Results (SEER) program,
1975-2014 there has been a 51% increase in CRC in those younger than 50 years of age. Also
noted was an increase in the incidence of rectal cancer. According to Howlander et al. (2019)
adults born around 1990 have twice the risk of colon cancer and four times the risk of rectal
cancer compared to adults who were born in the 1950’s. Also noted was an increase in incidence
in the white population and an increase in incidence and mortality with successively younger
birth cohorts. Sigel’s study (2017) has been labeled an epidemiological phenomenon. Colon
cancer rates have nearly doubled from the rates since the 1980’s. The researchers felt that the
study was not subject to bias arising from colonoscopy in the older cohorts because negligible
screening and case finding occur in the youngest cohorts. CRC mortality rates among whites
ages 30-39 years have increased since 1995, and have been decreasing in African Americans,
however, African Americans still have a 50% higher chance of developing colon cancer than
whites.
Purpose of Molecular Screening and Hereditary Cancer Questionnaire
The Human Genome Project commenced in 1990 and was completed in 2003. As a result
of this project scientists can identify gene variants that increase the chance of genetic disease. In
1994, the first BRCA1 breast cancer gene was discovered. This was monumental as it allowed
for increased surveillance in women who carry the gene. It also allowed women the option to
undergo elective mastectomy based on their risk of developing breast cancer.
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The field of gastroenterology can also benefit from genetic testing to help strategize on
when to start colonoscopy screenings and when to repeat colonoscopy screening. Approximately
three percent (1 in 30) of patients who are diagnosed with CRC have an inherited genetic
condition that can be identified by genetic testing. People with hereditary cancer syndrome are
more likely to develop CRC before the screening age of 50 years of age (Jenkins et al., 2015).
Mortality rates attributed to CRC have decreased 53% from 1970-2016 because of increased
screening and advances in technology and treatments (ACS, 2018). The increase in incidence of
CRC and mortality in patients younger than age 55 indicates the need for improved screening
and prediction models (Ma & Melson, 2018).
The application of molecular screening in clinal practice has a role in identifying patients
who are at risk for the development of CRC. Patients with known Lynch Syndrome are more
likely to get CRC, uterine, stomach, liver, kidney, brain, and skin cancer. In addition to
identifying patients with Lynch Syndrome it can aid in the identification of at-risk family
members. Lynch syndrome is caused by inherited genetic mutations which affect the DNA
sequence of replication. Lynch Syndrome is the most common autosomal dominantly inherited
cancer syndrome that predisposes a person to CRC. Mutations that have been identified in
Hereditary nonpolyposis colorectal cancer (HNPCC) include: MLH1 (chromosome 3p21);
MSH2 (chromosome 2p16); MSH6 (chromosome 2p15); PMS2 (chromosome 7p22, MLH3
(chromosome 14q24.3; and possibly PMS1. Most HNPCC associated cancers, (90%) arise from
mutations in MLH1 or MLH2 (Lynch et al..,2003). Once a patient has been identified as having
HNPCC/Lynch syndrome the screening colonoscopy changes from age 45-50 years of age to age
20-25 years with repeat colonoscopy every 1-2 years. The death rate of patients who have
HNPCC colon cancer compared to the general population of unknown or sporadic causes of
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colon cancer accounts for 66% of CRC related mortality. Early identification of HNPCC can
reduce mortality of colon cancer through colonoscopy and frequent screenings. A recent
prospective study (Jarvinen et al., 2000) included 22 families with Lynch syndrome comparing
cancer incidence and mortality between 133 at risk members who had undergone colonoscopy
screening over 15 years, and 119 members who declined screening. Individuals who underwent
colonoscopy screening every three years were found to have had a lower CRC incidence of six
percent as compared to 16% in the unscreened group (Jarvinen, et al.,2000) and a lower mortality
rate of eight percent as compared with the unscreened group of 22%.
HNPCC associated adenomas are believed to arise in the proximal or ascending colon
(60-80%). Adenomas in the proximal colon show a higher progression to high-grade dysplasia
and the development of colon cancer. Patients with Lynch Syndrome typically have polypoid
villous histology with a more rapid progression from polyps to carcinoid of 35 months compared
to 10-25 years in patients without Lynch Syndrome (Giardiello et al., 2014 ) Patients who have a
genetic mutation have an average mean diagnosis age of 27-46 years of age in comparison of the
mean age of sporadic cancer of 69 years of age. The diagnosis of HNPCC or Lynch syndrome
can be made by either immunohistochemical analysis of the MMR gene protein in tumors or by
DNA testing showing a pathogenic germline mutation in the DNA mismatch, MMR or EPCAM
genes. Germline testing on all patients suspected to have Lynch Syndrome can aid with early
diagnosis.
“It is becoming the standard of care at many centers that all individuals with newly
diagnosed CRC are evaluated for Lynch syndrome through molecular diagnostic tumor testing”
(Tomiak et al., 2014). Genetic testing involves either giving a blood or saliva specimen. Many
insurances will cover genetic testing if a patient meets criteria. Hereditary Cancer Screening
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Questionnaire is a prediction model that helps guide the healthcare team on recommended age of
screening procedures. Prediction models include family history of hereditary cancers (pedigree),
age, sex, and previous history of colon cancer to help identify and provide quantitative estimates
of the likelihood of a DNA mismatch. Although there are several models available, they all
include family history of hereditary cancers (pedigree), age, sex, and previous history of colon
cancer
Genetic labs use a multi-step approach to ensure the accuracy of genetic testing. The
early part of the process starts in the clinic where patients who have a significant family or
personal history of Lynch associated cancers submit a hereditary cancer screening questionnaire.
Informed consent must obtained prior to any genetic testing. The specimen is sent to a lab with
the patient’s demographics, insurance information, and hereditary cancer screening assessment.
Genetic counselors evaluate the hereditary cancer screening form and provider documentation.
Financial counselors work with payer sources to obtain coverage. If the patient does not meet
criteria per insurance guidelines cash payment and payment plans are accepted. The geneticist
evaluates the specimen for germline mutation. If the patient has a germline
mutation the gene that is affected is identified with a lifetime risk of developing cancer and
recommending screening protocols.
Clinical Question
Gastroenterology clinics are seeing an alarming number of young patients presenting for
colonoscopy for diagnostic issues that are incidentally diagnosed with adenomas. These patients
would not have undergone an initial screening colonoscopy until age 45-50 years old (AGA,
2018). A hereditary cancer screening questionnaire could aid in identifying patients who are
higher risk for the development of colon cancer (ACS, 2017). As advanced practice nurses, it is
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our responsibility to identify better ways to care for our patients. According to the Code of Ethics
developed by the American Nurses Association (ANA, 2015) “The nurse, in all roles and
settings, advances the profession through research and scholarly inquiry, professional standards
development, and the generation of both nursing and health policy.” With genetic testing being
available and highly reliable we can decrease mortality and incidence of colon cancer by
colonoscopy surveillance. This would allow providers to personalize a plan of care based on the
patient, considering society guidelines per the American Cancer Society. The purpose of this
study and integrative review was to identify if initiating a hereditary cancer screening assessment
in the clinic setting aids in early identification of patients who are at higher risk for colon cancer
and adenomas below the screening age of 50 years of age.
Thus, the purpose of this study and integrative review was to identify if initiating a
hereditary cancer screening assessment in the clinic setting aids in early identification of patients
who are at higher risk for colon cancer and adenomas below the screening age of 50 years of age.
PICO Question
In the outpatient gastroenterology clinic, for patients who present with issues that warrant
colonoscopy below the screening age, does implementation of a Hereditary Screening
Questionnaire have a positive or negative predictive value for risk of colon cancer and adenoma
detection rate.
Definition of Terms
The following definitions are included as they are directly related to this research and to
provide better clarity.
•

AACN Synergy Model – nursing theoretical framework designed by the American
Critical Care Nursing Association that has a core concept that synergy occurs when the
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needs or characteristics of the patients and families influence and drive the characteristics
or competencies of the nurse (AACN, 2018).
•

Adenoma – precancerous polyp (Merrian Webster,2020)

•

American Cancer Society (ACS) – one of the largest private, non-profit cancer research
funds ("About us | What is the American Cancer Society, 2018.)

•

American Gastroenterology Association (AGA) – Professional Medical Association
for Gastroenterologists (American Gastroenterological Association, 2019)

•

Colonoscopy – medical exam to evaluate the inside of the large intestines (Colonoscopy,
2018)

•

Computed Tomography Colonoscopy – three-dimensional model of the colon that a
radiologist uses to evaluate the bowel, also known as a virtual colonoscopy ("CT
Colonography," 2018)

•

Cologuard – stool test to identify DNA mutations and other abnormalities in the stool to
determine is a test is positive or negative ("At-home colon cancer screening test |
Cologuard® | Risk info," n.d.)

•

Colorectal Cancer (CRC) Cancer that arises from the colon/rectum ("About colorectal
cancer," n.d.)

•

FIT Test – fecal immunochemical test – screening test for blood in the stool ("Meet
Cologuard® | Learn about effectiveness | Risk info," n.d.)

•

Hereditary Cancer – Cancers that are more likely to present in patients wo have
genetically identified gene mutations. ("Lynch syndrome," 2020)

•

Lynch Syndrome – autosomal dominate condition, most common cause of inherited
CRC. The eponym “Lynch syndrome” is named after Dr. Henry T. Lynch who is credited
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for discovery of this condition. The designation applies to families and patients with a
germline mutation in an MMR gene of loss of expression of the MSH2 gene due to
deletion in the EPCAM gene ("Lynch syndrome," 2020)
•

HNPCC – Hereditary nonpolyposis colorectal cancer syndrome. This term may be used
interchangeably with Lynch syndrome. It is an autosomal dominant genetic condition that
is associated with a high risk of colon cancer. HNPCC is associated with germline
mutations of DNA mismatch (American Gastroenterology Association, 2017)

•

Mortality – death associated with a condition, for the purpose of this study mortality
relates to deaths associated with colon cancer

•

Occult Blood – blood in stool

•

Colon polyp – abnormal tissues growth in the colon, polyps can be characterized by their
pathology as malignant, adenomatous, hyperplastic, or inflammatory

•

Polyposis syndrome – Identified in patients who have greater than 20 lifetime adenomas,
patients with a personal history of desmoid tumor or other extracolonic manifestations of
familial adenomatous polyposis (FAP), (American Society of Colon and Rectal Surgeons,
2016)

•

Sigmoidoscopy – evaluation of the sigmoid colon with either a colonoscope of
sigmoidoscope ("Definition of sigmoidoscope," n.d.)

•

The U.S. Preventive Task Force (USPTF) – independent, volunteer panel of national
experts in disease prevention and evidence-based medicine

Theoretical Framework
The theoretical framework (see Figure 1) chosen to support this research was the AACN
Synergy Model of care. The AACN synergy model was created by a group of nurses
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representing the American Association of Critical Care Nurses (Swickard, Swickard, Reimer,
Lindell, and Winkelman, 2014). The Synergy Model was intended to put the focus on the needs
of the patient and the competencies of the nurse. According to the AACN, synergy results when
the needs and characteristics of a patient, clinical unit, or system are matched with a nurse's
competencies (AACN, 2016). The model described seven characteristics that a patient will
manifest during various phases of their illness: stability, complexity, predictability, resiliency,
vulnerability, participation in decision, making and care, and resource availability. This
theoretical framework applies to this study as it puts the focus on the patient and uses the skills
and knowledge of the advanced practice nurse to improve patient outcomes. The role of
molecular biology and genetic screening is complex but has a purpose in predictability of a
disease and illness. Decision making for colonoscopy before the screening age on vulnerable
patients at risk due to their history can be enhanced using hereditary screening tools as a valid
resource.
The Adventist Framework Model has three key constructions including caring,
connecting, and empowering. Nursing as a profession, is known for their culture of caring. The
primary concept of caring means that nursing practice and patient care should evolve with
evidenced based practice guidelines to alleviate suffering and disease processes. Genetic testing
falls into this category as it is evidence based and can prevent colon cancer. The second concept
is connection. Healthy relationships are derived from connecting with people. Ellen G. White
wrote that “Christ came to the earth and stood before the children of men and through our
connection with Him we are to receive, to reveal, and to impart.” ("Counsels on Stewardship,"
1886). Her words tell us that for us to connect with our patients we must connect on a physical,
psychological, and spiritual levels. Our goal is to create positive outcomes and trust with the
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people we are have been entrusted to care. The last concept in this model is empowering.
Empowering means that we provide quality care to improve patient care. As evidence has shown,
the gold standard for prevention of colon cancer is colonoscopy (ACS, 2017). The screening age
as previously mentioned is 50 years old. With genetic testing we can identify patients who have a
hereditary predisposition to developing adenomatous colon polyps at an age younger that 50 of
age. Genetic anomalies can be detected now because of the Human Genome Project. Individuals
with an HNPCC gene mutation have an estimated 80 percent lifetime risk of developing colon or
rectal cancer (NIH, 2012).
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Conceptual Model- AACN Synergy Model Adventist Framework
Biomolecular Screening for Adenomatous Colon Polyps
Advanced Practice Nurse

Caring
Nurse Practioner

Patient Needs

Clinical Inquiry

Quality of Life

Patient Advocacy

Trust and Comfort

Systems Thinking

Complexity and Vulnerability

Moral Agency

Resource Availability

Figure 1: American Association of Critical Care Nurses (1996) From American Association
of Critical Care Nursing Synergy Model. Retrieved from (https://www.aacn.org/nursingexcellence/aacn-standards/synergy-model).
Adventist Framework for Nursing (2017) Patricia S. Jones et al., “A Distinctive Framework
for Adventist Nursing,” The Journal of Adventist Education 79:5 (October-December 2017): 413. Available at https://jae.adventist.org/en/2017.5.2.
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CHAPTER 2
Review of Literature

The topic of the review this literature is colon cancer and hereditary genetic conditions
such as Lynch syndrome and HNPCC and how genetic testing would be beneficial to implement
as a screening tool for patients under the age of 50 years who are at risk for developing
adenomatous colon polyps. A search of the following databases was conducted: CINAHL
complete (from 2009-present), the AACN website, American Gastroenterology Association,
American College of Gastroenterology, National Institute of Health, National Comprehensive
Cancer Network, UpToDate, Centers for Disease Control, American Cancer Society and Google
Scholar. The key words that were searched included the following: colon cancer, genetic testing,
hereditary nonpolyposis syndrome, Lynch syndrome, adenomatous colon polyps, colonoscopy
screening guidelines, and prediction tools for colon adenomas.
Society Guidelines for Colon Cancer Screening
The American Gastroenterology Association along with the U.S. Multi-Society Task
Force of Colorectal Cancer (MSTF) which represents the American College of Gastroenterology,
the American Society for Gastrointestinal Endoscopy updates the screening recommendations for
screening colonoscopy. Three tiers of colon cancer screening have been identified with tier one
considered the gold standard and cornerstone of surveillance methods. Colonoscopy screening
should begin at age 50 and age 45 for African Americans of average risk. Tier one screening
involves colonoscopy every 10 years and an annual fecal immunochemical test (FIT). Second
tier testing includes CT colonography every five years and FIT-fecal DNA test every 3 years,
and a flexible sigmoidoscopy every five to ten years. Screening colonoscopy should be offered to
patients up to the age of 85 if they have not had previous colonoscopy. Cessation of screening
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colonoscopy should be considered at age 75 or with less than 10 years of life expectancy (Rex, et
al., 2017)
Average risk patients start colorectal cancer screening at age 45 regardless of ethnicity
(ACS, 2018). Patients over the age of 85 should no longer have colonoscopy screening. In May
2018, the ACS, lowered the age to started screening at age 45 instead of 50 due to the increasing
number of new cases of colon cancer in younger adults (National Cancer Institute, Surveillance,
Epidemiology, and End Results Program 2018).
Society Recommendations for Evaluation of Patients with Lynch Syndrome
Lynch Syndrome is the most common heritable cause of colorectal cancer and accounts
for up to three percent of colorectal cancers. Patients who are diagnosed with Lynch syndrome
have a cumulative incidence of colorectal cancer up to 80% in a lifetime. Patients with a family
history suggestive of Lynch syndrome with no personal history of colon cancer should be offered
a predictive model to evaluate their probability of having Lynch syndrome (American
Gastroenterology Association, 2015). Patients who have greater than five percent on a prediction
model should have genetic germline testing (Rubenstein, et al., 2015)
Lynch syndrome patients have a higher risk of developing colorectal cancer. Most
colorectal cancers in patients with hereditary cancer develop before the age of 50 (American
Cancer Society, 2017). Patients who have Lynch syndrome should start their colonoscopy in
their early 20’s and have colonoscopy every 1-2 years for surveillance (National Comprehensive
Cancer Network, 2015). Genetic testing is advised for family members of patients with Lynch
syndrome.
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Colon Cancer Incidence Rates and Adenoma to Carcinoid Progression Rates
The best way to prevent colon cancer that is associated with Lynch syndrome CRC is
through screening colonoscopy (ACS, 2018). Through regular screening colonoscopy in patients
with Lynch syndrome, mortality is decreased by 67% (Niv et al., 2014). Studies to estimate age
and sex specific colorectal cancer risks have been unsuccessful due to sample sizes being too
small to produce reliable data. A meta-analysis of 1,114 Lynch syndrome families with MLH1
and MSH2 mutations were studied to better estimate age and sex specific short-term risks of
CRC in patients with Lynch syndrome (Jenkins et.al, 2015). The estimated cumulative risk of
CRC by age 70 ranged from a 27%-47% for males and 22%-37% for females. The hazard ratio
for CRC decreased with age being the highest when they were ages 30-39, and lowest after age
70. This study estimates by applying hazard ratios to the US general population that 1.4 % of
male carriers and 1.0 % of female carries between the age of 20-29 will be diagnosed within five
years. Short-term risk of CRC in patients with Lynch syndrome is dependent on age, increasing
rapidly until middle age. While yearly colonoscopy in their 20’s may not be indicated, annual
colonoscopy for those older than 30 should be required to help in the early identification of
symptoms, and thus to prevent the development of colon cancer (Jenkins et al., 2015)
The increasing incidence of young adults who have been diagnosed with colorectal
cancer was assessed by Sinal et al, (2017). CRC incidence trends were taken from 1974-2013
(n=490,305) and analyzed by five-year age group and birth cohort. From the mid 1980’s through
2013 the diagnosis of CRC in adults ages 20-29 increased 2.4%; for ages 30-39 there was a one
percent increase; and ages 55 and older the incidence rate declined. In the mid 1990’s rates
increased 1.3% in younger adults for ages 40-49. Also noted was that people under the age of 50
were more likely to have distal colon tumors whereas people over the age of 50 were more likely
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to have proximal colon tumors. CRC screening at age 45 is not yet supported by all insurance but
it is worth noting that in 2013 there were 10,400 new CRC diagnosis in adults age 40-49.
Colonoscopy findings from 54 people with pathogenic mutations in MSH2 and MLH1
were evaluated for the development of CRC in patients with Lynch syndrome (Edelstein et al.,
2011). Differences in colorectal phenotype were analyzed with genotype and dwell time was
calculated for advanced neoplasms. Among mutation carriers the cumulative risk of CRC by age
40 was 43% and 72% by age 80. Polyp dwell time from advanced adenomas to colon cancer was
33 months plus or minus 16.2 months for people under the age of 40 and 35.3 months plus or
minus by age 80 (p=.198). Annual colonoscopy screenings and surveillance for patients with
Lynch syndrome based on short adenomatous polyp to carcinoma dwell time were recommended
(Edelstein et al., 2011). Limitations include a small number of patients and failure to find
statistical analysis of colorectal neoplasia distribution by mutation type or the chance occurrence
of a high risk of CRC in women. Selection bias was also a concern.
Frequency and Prevalence of Colon Adenomas in Patients with Genetic Variants
The frequency and spectrum of cancer susceptibility genetic mutations among colorectal
cancer diagnosed under age 50 were studied. Patients with colorectal cancer younger than age 50
were accrued. Germline DNA was tested for mutations in 25 cancer susceptibility genes using
gene sequencing. Of the 450 patients with early-onset CRC, 75 pathogenic genetic mutations
were found. Thirty-six patients (8%) had Lynch syndrome. Patients with pathogenic mutations
were more likely to report a family history of CRC (45.8% vs 14%; P<.001).
The frequency of the factors associated with genetic testing of first-degree relative of
Lynch syndrome probands were assessed in study by Sharaf, Myer, Stave, Diamond &
Lababaum, 2011. They found that 52% or less of first-degree relatives of Lynch syndrome

SCHOLARLY PROJECT

25

probands received genetic testing. Genetic testing is underutilized by first degree relatives of
patients with Lynch syndrome.
Colonoscopy and pathology records of patients were studied to document the number of
adenomas in patient with Lynch syndrome (Kalady, Kravochuck, Heald, Burke & Church,
2015). A total of 263 patients with a germline mutation in one of the four DNA mismatch repair
genes were included. A total of 107 of the 263 patients had one or more adenomas, 61 patients
had one adenoma, 29 patients had two to five adenomas, and 11 patients had 20 or more
adenomas. The maximum number of synchronous adenomas was 22 and the maximum
cumulative was 24. Of the 220 patients (54%) had hyperplastic polyps, 313 adenomas were
found on colonoscopy, and 123 of the adenomas were advanced.
Barriers to Biomolecular Genetic Testing
Factors involved in the implementation for universal Lynch syndrome screening were
evaluated via interview with health-plan and clinical stakeholders at large HMO companies.
Prior to the implementing the study (Schneider, et al., 2015) estimated only five percent of CRC
were screened for Lynch syndrome relying on providers or self-referrals. Open-ended interviews
phase one consisted of responsibilities of Lynch Syndrome screening, perceived impact on
department workflows and staff, concerns about implementing universal screening, and factors
that facilitate screening. Phase 2 focused on asking about the potential to establish universal
Lynch syndrome screening and their perceived value of change in the organization. Participants
included representatives from pathology, oncology, medical genetics, gynecology, surgery,
laboratory service, and healthcare administration.
Most people felt Lynch syndrome screening should be standard practice of the
organization metric to improve CRC screening and prevention. Half or more advocated for
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Lynch screening stating it is the “right thing to do” for patients. The participants in the study felt
that the United States was behind on screening options for CRC and many leaders expressed that
they did not know who was implementing national recommendations for CRC prevention.
Barriers that were addressed were fear of health insurance discrimination, enough time with
already heavy workloads on staff, and uncertainty on who would be responsible for testing.
Colorectal Cancer Screening for Average-risk adults: 2018 Guideline Update from the
American Cancer Society
A recent observational study by Siegel et al. (2017) was performed to trend incidence
rates of colon cancer. The study found a 51% increase in the amount of colon cancer being
diagnosed in individuals under the age of 50 years old since 1994. The analysis showed that
adults born around 1990 had twice the risk of colon cancer and four times the risk of rectal
cancer compared to those born in 1950. Colon cancer has varied by sex, race, and ethnicity. The
incidence of colon cancer is similar in men and women until the age of 35 and then increases in
men. Incidence rates in African Americans are declining although, they are still historically
higher than whites. Mortality rates among the white population have increased since 1995 in
ages 30-39 and have decreased in African Americans since 1970. Due to the increase in mortality
and incidence noticed in trends the American Cancer Society changed its recommendation to
start colonoscopy screenings at age 45 instead of 50 due to the potential early detection and
prevention benefit for adults ages 45-49 years of age. The USPSTF continues to recommend
screening to begin at age 50 years of age and recommends flexible sigmoidoscopy every 10
years combined with an annual FIT test.
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American Gastroenterology Lynch Syndrome Management
Patients who have been identified with a genetic variant are diagnosed with Lynch
syndrome. These individuals develop adenomas at a younger age, the adenomas have a
predominance to the ascending colon with a shorter conversion time to an adenocarcinoma.
People who took up colonoscopy surveillance that were identified with having Lynch syndrome
had 65% (p=0.03) fewer deaths in comparison to those who refused colonoscopy (Jarvinen,
1995). For the purpose of this study the American Gastroenterology Association (AGA)
recommends persons who have been diagnosed with Lynch syndrome or have a first degree
relative with Lynch syndrome begin colonoscopy at age 20-25 and repeat every 1-2 years. This is
considered a strong recommendation, with evidence level 3 and GRADE moderate-quality
(AGA, 2014)
Barriers to Research
This review of literature revealed an upward trend in the younger population particularly
patients diagnosed around the 1980’s. Little is known as to why this generation seems to be
targeted. Genetic testing is now available and is a reliable tool to identify patients who are at risk
for developing aggressive cancers at a younger age. Patients who have Lynch
syndrome have a 25% risk of developing colon cancer by age 50 and a 90% chance of
developing other Lynch syndrome associated cancers in their lifetime. Patients who answer
positive to a medical questionnaire will benefit from genetic testing specifically if they have
colorectal or endometrial cancer before the age of 50 or two or more Lynch syndrome cancers at
any age (Myriad Lab, 2018). Many studies have been done assessing patients who have a known
history of genetically associated cancers. However, the review of literature does not demonstrate
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Chapter 3
Methodology

Purpose Statement
The purpose of this project was to determine if there is an association between hereditary
cancer, gender and the incidence of colon adenomas and colon cancer in patients under the
screening age of 50 years. The concept of implementing a hereditary cancer screening tool and
lifestyle assessment as a predictive tool for people between the ages of 18-49 years old was
explored due to data showing a rise in incidence of colon adenomas and colorectal cancer (ACS,
2018). In patients without a personal history of colorectal or another cancer but with a family
history suggestive of Lynch syndrome, the American Gastroenterology Associations suggests
that risk prediction models be offered rather than doing nothing (Rubenstein, Enns, Heidelbaugh
& Barkun, 2016).
Objective
A quality improvement project was implemented to evaluate the feasibility and
effectiveness of implementing the hereditary cancer screening questionnaire in patients between
the ages of 18-49 years of age in the gastroenterology clinic. The objective was to evaluate if
there is an association between a family history of hereditary cancer, gender, and premature
diagnosis of adenomatous colon polyps. If association is statistically significant, this tool could
be of value for primary care providers to identify people who are at higher risk for development
of premature adenomas warranting referral to gastroenterology providers for further evaluation.
The overall objective was to identify and reduce the incidence of colon cancer in people between
the ages of 28-49 years of age. Patients deserve a personalized plan of care and need to be armed
with the best tools available for the early detection of colon polyps to potentially prevent
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colorectal cancer. Early detection and resection of precancerous polyps are critical to interrupt
the adenoma-carcinoma sequence and prevent the development and spread of CRC (Simon,
2016). This information could be used to help improve health and quality of life and reduce
healthcare costs.
Design
The project design was a retrospective correlational study to evaluate if patients who test
positive to a hereditary cancer screening have a statistically significant correlation with the early
development of adenomas below the screening age. The patient BMI, age, gender, number of
positive factors identified on the questionnaire were recorded. The dependent variable was
colorectal adenoma by colonoscopy evaluation. The independent variables tested were gender
and a personal history of genetically associated cancers: colorectal, endometrial, ovarian, and
gastric cancers.
Procedure
Several steps were taken in the construction of this project. A problem was identified in
the gastroenterology clinic. Several patients were incidentally diagnosed with adenomatous
colon polyps who underwent colonoscopy for diagnostic purposes under the age of 50 years. A
review of literature was done to assess ways to identify patients who are at risk for the early
development of colorectal cancer. Hereditary cancer screenings were recommended by the
American Cancer Society and the National Institute of Health. The Amsterdam Criteria was
chosen as a tool to identify whether a patient had relatives that were diagnosed with cancers that
can be genetically associated (UpToDate, 2019). All patients were asked to fill out a hereditary
cancer screening questionnaire that assessed a personal history, first degree family history,
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second degree family history, and extended family history of genetically associated cancers
(Appendix G).
The procedure for this project was based on the American Association of Critical Care
Nurses Synergy Model. The fundamental part of the study was focused on the patient and disease
prevention. Patients who underwent diagnostic colonoscopy between the ages of 18 and 49 were
included. Anyone who presented for a screening colonoscopy were excluded from the study.
Data were collected from the EMR GMED after colonoscopy and the results of their findings
including: location of polyp, type of polyp per pathology report done by Path Group,
demographics, as well as answers to their hereditary cancer screening questionnaire were
imported into a password protected excel file until the project was completed. Consent was
implied as patients sign a general consent when they present to the office. Patient names were
replaced with case study numbers and manually entered into SPSS for statistical analysis.
Description of Measures
For the purpose of this study the incidence of colorectal adenomas was measured with a
personal history of genetically associated cancers and age. Colorectal adenomas were detected
by colonoscopy. Once the polyp was removed it is sent to pathology for evaluation on the type of
adenoma. Adenoma progression rates vary from the site, size, and type of adenoma. A polyp
starts out as a small growth of excess tissue in the lining of the colon. Not all polyps turn into
cancer. There are two shapes of polyps (sessile and pedunculated); and five types of polyps
(tubular adenoma, hyperplastic, serrated, inflammatory, and villous adenomas). The
development of more than 70-95% of colorectal cancer can be prevented by early detection and
removal of colon polyps (AGA, 2017). Sessile serrated polyps have a 20-30% chance of
developing into a neoplasm (Makkar, Pai, & Burke, 2012), 91% being in the proximal colon. A
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quality improvement initiative for gastroenterology has been implemented to increase the
adenomas detection rate by colonoscopy to prevent colon cancer (Gurude, et al., 2018). Patients
who have Lynch syndrome have an adenoma-carcinoma progression rate of 35 months versus
10-15 years (ACS, 2018). There are often no symptoms of colon polyps, making surveillance
and identification of patients more important. Genes that have been identified in the development
of colon cancer associated with Lynch syndrome include: MLH1, MSH2, MSH6, PMS2, and
EPCAM gene (Win & Lindor, 2019).
The Amsterdam 1 criteria Hereditary Cancer Screening Questionnaire (Appendix G) was
developed to identify patients who are likely to be mutation carries for Lynch syndrome. This
prediction model provides quantitative estimates of the likelihood of mismatch repair mutation
(American Gastroenterology Association, 2001). Patients between the ages of 18-49 who
presented to the gastroenterology clinic were provided with a hereditary cancer screening
questionnaire that was developed from the Amsterdam1 criteria. A detailed family history of
Lynch syndrome associated cancers was documented. Patients who qualified for colonoscopy
underwent diagnostic colonoscopy. The number of adenomatous colon polyps were compared to
the hereditary screening survey and patients’ gender. Patients who met criteria for germline
testing either by questionnaire or colonoscopy were offered genetic testing. Relationships
between screening factors and diagnosis of adenoma were determined by statistical analysis per
SPSS software.
Protection of Human Subjects
Ethical considerations ensured minimal to no risk to study participants. Data retrieval was
kept in a password protected excel document and later imported into SPSS with a case number
being assigned to each patient for privacy protection. Patients were evaluated and treated in
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accordance to the American Gastroenterology standards. There were no unnecessary procedures
ordered on patients for the purpose of this study. Patients who scored high on the hereditary
cancer screening questionnaire were educated on their risk factors and offered genetic testing if
warranted. HIPPA compliance was maintained. All patients received post-procedural counseling
and education on their findings. No personal patient identifiers were published. Data collection
was done by the primary researcher and with the assistance of the attending physician, and
medical assistants. Children were excluded from the study as the research site was credentialed
to take care of adult patients only. The project was sent to the IRB committee and was approved
on July 26, 2019 as an expedited review (Appendix F).
Evaluation Plan
Descriptive statistics were generated to display associations between participants, gender,
and family history of hereditary cancers. Chi square goodness of fit contingency table were used
to analyze the data. G-Power was set at a goal of 95% which would include 145 chart reviews to
a minimum of 88 chart reviews to achieve an 80% power. Frequency tables were used to
evaluate age, gender, BMI, and smoking status in correlation with the presence of colon
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Chapter 4

Analysis of Results Description of Sample/Population
The sample was taken from a gastroenterology clinic in East Tennessee using G-Med
and Pathogroup Electronic Medical Records (EMR). Patients who had colonoscopy exams
between January 1, 2019 and December 31,2019 were considered. Exclusions for this study
included anyone over the age of 49 years old, who would have been normally eligible for
colonoscopy. There were 150 patients total that met criteria for the study. Of the 150 total
subjects 59 (39.3%) were males and 91 (60.7%) were females. The mean age of the sample was
40.14; Median 44; Mode 48; with an age range from 18-49 years old. The average patient was
obese with a mean BMI of 32.85. There were 115 (76.7%) patients who said they were nonsmokers and 35 (23%) who did smoke.
Hereditary Genetic Screening Survey
Three out of 150 patients (2%) reported a personal history of cancer with breast and
endometrial being the most common. Patients who reported having first degree relatives with a
history of cancer included 49 (32.7%) of the sample with the most common cancer being
colorectal 17 (11.3%); breast 6 (4%); followed by pancreatic 5 (3.3%); and ovarian 5 (3.5%).
Second degree relatives with a history of cancer were reported by 42 (28%) of the sample with
colorectal 16 (10.7%), other 10 (6.7%), and breast 8 (5.3%) being the most common. Patients
who reported extended family members with cancer were 41 (27.3%) people in the study with
the leading reported cancers being colorectal 11 (7.3%), breast 14 (9%); and pancreatic 6 (4%).
Pathology
Patients diagnosed with colon adenomas included 58 (38.7%) participants. The percent of
patients with hyperplastic polys which have zero chance of developing into an adenocarcinoma
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included 29 (19.3%) of the sample. The most common location of the adenoma was the
ascending colon 21 (14%) followed by the transverse colon 17 (11.3%), and the rectum 15
(10%). The most common type of adenomas was tubular adenomas 37 (24.7%), and sessile
serrated adenomas 19 (13%).
Research Problem
This study was performed to see if there was a correlation between patients answering
positive to a hereditary cancer screening and the detection of early adenomas. The dependent
variable was colon adenomas with the independent variables answering positive to a hereditary
cancer screening. Co-variables included sex, age, smoking status, BMI, first, second, and thirddegree relatives with hereditary cancer. Other co-variables included the location of the polyps,
the type of pathology, and the type of cancer reported on the hereditary cancer screening tool.
Analysis of Project Question
The purpose of this study was integrative review to identify if initiating a hereditary
cancer screening assessment in the clinic setting aids in early identification of patients who are at
higher risk for colon cancer and adenomas below the screening age of 50 years of age. A ChiSquare Goodness of Fit test was used to calculate whether there is a statistically significant
relation between having a history of heredity cancer and early onset adenomas. Analysis of
personal history, first degree and higher history of hereditary cancers, second degree family
history, and extended family history were completed.
Personal History of Hereditary Cancer and Adenoma Detection
Of the 150 charts reviewed, three patients (2%) reported a personal history of hereditary
cancer, one with breast cancer, one with endometrial cancer, and one with “other” cancer. A chisquare goodness -of-fit was conducted to determine whether the patients that reported a personal
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history of hereditary cancer had early onset adenomas. The chi-square goodness-of-fit test
indicated that there is not a significant difference in the occurrence of adenoma on colonoscopy
for individuals who give a positive versus negative personal history X²(1) = 1.012, p = 0.314).
First Degree Family History of Hereditary Cancer and Adenoma Detection
Of the 150 patients reviewed, 49 (32.67%) reported a first-degree family history of
hereditary cancer with pancreatic, breast, and colorectal cancer being the most common. The chisquare goodness-of-fit test indicated that there is not a significant difference in the occurrence of
adenoma on colonoscopy for individuals who give a positive versus negative first degree family
history,(X²(1) 3.264=, p=.071)
Second Degree Family History of Hereditary Cancer and Adenoma Detection
Of the 150 patients reviewed, 42 (28%) reported a second-degree family history of
hereditary cancer with colorectal, “other”, and breast cancer being the most common. The chisquare goodness-of-fit test indicated that there is a statistically significant association in the
occurrence of adenoma on colonoscopy for individuals who give a positive versus negative
second degree family history (X²(1) = 5.347, p =0.021).
Extended Family History of Hereditary Cancer and Adenoma Detection
Of the 150 patients reviewed, 41(27.2%) reported extended family history of hereditary
cancer with pancreatic, breast, and colorectal cancer being the most common. The chi-square
goodness-of-fit test indicated that there is not a significant difference in the occurrence of
adenoma on colonoscopy for individuals who give a positive versus negative extended family
history (X²(1) .486=, p=0.486).
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Additional Statistical Analysis
Gender
Of the 150 patients reviewed, 59 (39.3%) were male and 91(60.7%) were female. A chisquare goodness-of-fit indicated that gender had no effect on the occurrence of adenomas (X²(1)
=.563, p=.453)
Smoking
Of the 150 patients reviewed, 73 (48.6%) were non-smokers and 42 (28%) were smokers.
A chi-square goodness-of-fit indicated that smoking status had no effect on the occurrence of
adenomas (X²(1) =.956, p=0.328)
Prevalence Rates
Prevalence rates were calculated on total of all patients who answered positive on a
heredity cancer screening questionnaire as well as the presence of colon adenomas. In addition,
positive and negative predictive values were calculated. Prevalence rates of patients who
reported a positive history or family history of hereditary cancer was 44.67%. The prevalence of
patients who were found to have colon adenomas on a colonoscopy examination was 38.67%.
The sensitivity of the questionnaire for predicting adenoma as 40.96%, and the specificity was
64.18%. Positive predictive value (PPV) was 58.62% with a negative predictive value (NPV) of
46.74%.
Table 1
Hx +

Hx -

Adenoma +

34

24

Adenoma -

49

43
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Unintended Consequences
During this review, Blue Cross Blue Shield of Tennessee changed the age for
colonoscopy screening to start at age 45 instead of 50 years of age. This was done in response to
the American Cancer Society position statement that was issued to the public on May 31, 2018.
Blue Cross Blue Shield made this change effective October 1, 2019. Several other insurance
companies followed the same change. The population studied were people under the age of 49
years old. The National Conference of State Legislators Colorectal Cancer Screening Laws by
State (2010) state that “All individual and group plans mandate offering individuals defined by
the American Cancer Society (ACS) as average risk follow in accordance with the ACS
screening options,” As a result, the data extracted from patient files between October 1, 2019 –
December 31, 2019 reflected this change.
Summary
The sample included a total of 150 participants. Most of the sample were women. The
mean BMI of the sample size was 32.3 indicating that most were obese. Most of the population
were non-smokers. Adenomas (pre-cancerous colon polyps) were found in 38.7% of the sample
with the most common location of the polyps being in the ascending colon. Hereditary Cancer
Screening Questionnaire was done and 2% reported a personal history of hereditary cancer;
32.6% reported a first degree family history of hereditary cancer with colorectal cancer being the
most common; 28% reported a second degree history with colorectal cancer being the most
common; and 27.2% reported extended family history of hereditary cancer with pancreatic;
breast and colorectal being the most common.
Statistical analysis indicates that there was not a significant relationship to answering
positive on a hereditary cancer screening questionnaire and adenomas found on colonoscopy
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with a personal history; 1st degree relatives; and extended relatives. Patients who reported yes to
a second-degree family history of colorectal cancer showed a significant association with
adenomas found on a colonoscopy.
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Chapter 5
Discussion of Findings

Relationship of Outcomes to Research
The purpose of the study was to evaluate if answering positive to a hereditary cancer
screening questionnaire was predictive of people who were at risk for the development of
premature adenomas. While patients who answered positive on a hereditary screening
questionnaire for personal history, first degree history, and extended history did not show an
association with adenomas on colonoscopy; second degree family history did show a significant
correlation. Smoking and gender also did not have a significant effect on the findings of colon
adenomas.
The hypothesis was that people who fall below the screening age and answer positive to a
hereditary cancer screening would be more likely to have adenomas found during colonoscopy.
A statistically significant association in the occurrence of adenoma on colonoscopy for
individuals who give a positive versus negative second-degree family history (X²(1) = 5.347, p
=0.021) was found. Patients with a positive personal history, first degree relative history, and
extended history did not show an increase in incidence of early adenoma. The hypothesis was
partially correct in that there was a significant relationship with people who presented for early
adenomas that had a second decree history of hereditary cancer syndrome.
Observations
During the study it was observed that many patients did not know their family history.
Some of the patients guessed on what they thought was their family history. Many patients did
not realize the relevance of genetics and chronic disease. Patients who presented with rectal
bleeding were much more concerned about getting their colonoscopy done as soon as possible
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than patients who presented with diarrhea, constipation, or a change in bowel habits. Many
patients exhibited fear of doing a colon prep and admitted this is what deterred them from having
a gastroenterology visit and colonoscopy.
Limitations
Several limitations were noted on the study. First and foremost, the sample size was
relatively small to answer the research question. The knowledge of the participants on their
family history was not equally distributed. Some patients were very confident of their family
pedigree and others were speculating what they thought was their family history. Patients who
were adopted were only able to fill out a partial family history based on their knowledge and
probably should have been excluded.
Other factors that may have influenced the study include they type and quality of the
colon prep that was used. The quality of the colon prep can impact the endoscopist’s ability to
identify colon polyps, specifically in the right colon. Patients who had co-morbid conditions
were not separated from patients who were relatively healthy and presented with subtle
symptoms. Additionally, the data were entered manually from one database to another. Human
error in data transfer may have occurred.
Implication for Future Research
Many studies have been done to identify the cause of colon cancer and to predict people
who are at risk for premature adenomas. Genetics are often used after a patient has been
diagnosed with colon cancer to determine if there is a genetic variant to strategize future care and
as a risk assessment for family members. Hereditary genetic testing is relatively new to
gastroenterology as far as a pre-assessment for patients for colon cancer. Future research to
support this would include a larger sample size and a wider demographic area.
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Colonoscopy remains the gold standard for colon cancer screening. It is an invasive
procedure that deters some people as they seek to avoid due to an unpleasant colon preparation
and the invasiveness of the test. Virtual Colonoscopy is a CT scan that is non-invasive however
and is an alternative to patients who do not want to have a colonoscopy. Future studies may
include a combination of virtual colonoscopy with genetic screening to identify patients that are
at risk. Another option may be to offer genetic screening to everyone at an early age to identify
the high-risk patients and proceed with screening exams.
Implications for Practice/Health Policy/Education
Colon cancer can be prevented by early detection of adenomas and removing them before
they convert to an adenocarcinoma. Use of a combination of known factors is needed to identify
patients who are at increased risk. Gastroenterology clinics need to educate primary care to be
aware of new screening tools as well as the reliability of these tools. Cologuard is often used as
the preferred method of screening colonoscopy by primary care however, it is not appropriate to
use in people who have a personal history of colon polyps or a strong family history of colon
cancer. Providers must be credulous in their committed to continued education and keeping up
with evidence-based practice.
One of the findings that was not recorded in the study that was noticed was hesitancy of
the patient to come to the GI clinic based on fear of rumors of how bad the colon preparation
would be and fear of colonic perforation. In response to these fears, the practice plans to launch
on their website the preparation that we use and how it works. Previously patients had to drink a
gallon of a hyperosmotic colon prep that made them nauseated and had a sour taste. New preps
are available that are only 6 ounces of medication with most of the prep being water. The
providers have also decided to create a colon preparation “survival kit” which includes flushable
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wet wipes, barrier ointment, anti-emetics, and 24-hour access to a provider in the event the
patient has a question or issue with the prep. Video example of the colon prep on the office smart
boards provide the link so patients can watch it at home. Each patient can look at a sample of the
colon prep, watch the video, speak with a nurse about the prep and go home with written
instructions to resolve their fears.
During this project health care policy was used to challenge insurance companies to
cover screening colonoscopy at age 45 instead of age 50 due to the new recommendation set by
the American Cancer Society. The American Cancer Society changed its protocol in 2018,
however, insurance companies were still not covering a screening until age 50. The local
Senator, Mike Bell, was contacted via email (Appendix C) about this concern. He is appointed
over the Health Board in Tennessee. Senator Bell responded to the email and ensured he would
address at the Capital. Approximately one month later our office received a letter from Blue
Cross Blue Shield of Tennessee that they will begin covering screening colonoscopy at age 45
according to ACS guidelines. This is an example of how nurse practitioners and legislators work
together as a team to promote health for the community. This new ruling will allow colonoscopy
and polyp diagnosis in the age range of 45-50 years of age and remove them before they progress
to an adenocarcinoma.
Conclusion
Doctorally prepared nurses have an obligation to protect, promote, and restore health to
the community. It is our duty to continue to find ways to improve healthcare through evidencebased practice and personally involvement in research. APN’s must always continue to strive to
find newer and better ways to educate and treat people. For the purpose of this project, there was
not a strong correlation with hereditary cancer screening and the diagnosis of early adenomas.
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However, there was a significance with patients who had second degree family history of Lynch
associated cancer and colon cancer.
Hereditary cancer screening is a simple form that is non-invasive and may enlighten
healthcare providers on patterns found in a person’s pedigree. This tool would be helpful with
assessment of other risk factors that are known to be linked to colorectal cancer including: diet
high in red meat, alcoholism, smoking, and obesity (American Cancer Society, 2019). Having
individualized care plans for each patient allows providers to strategize care based on that
specific person. APNs must continue to look for better ways to practice, while being open to
accepting new technology and medical advancements that may seem overwhelming and
challenging.
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Appendix C
Dear Senator Bell,
My name is Samantha L. Spinks. I am a board-certified acute care nurse practitioner in
Cleveland, TN. I work at East Tennessee Gastroenterology. I am also a board member of
Foundation House Ministries in Cleveland, and if I recall, you have attended one of our banquets
in the past. The purpose of my letter is that I am asking for legislative help and guidance on an
issue that is very important to me and my patient population. Colorectal cancer is the third most
common cancer in men and women in the United States (American Cancer Society, 2017) and
the second leading cause of cancer related deaths in the United States (JAMA, 2016). In 2018,
based on observational study from data recorded by the Surveillance, Epidemiology, and End
Results (SEER) program (1975-2014) by Siegel et al. the American Cancer Society changed its
recommendations to start colonoscopy screenings at age 45 years instead of age 50 due to an
increase in incidence rates and mortality in Americans under the age of 50 years of age with no
epidemiological evidence explaining the cause. There has been a 51% increase in CRC in those
younger than 50 years of age. As a nurse practitioner in GI, this concerns me greatly. We have
recently implemented a genetics program to help identify patients who are at elevated risk due to
genetic variants however, this is also insurance dependent.
Depending on state laws insurance companies cover screening colonoscopy at 45 years of age if
their state follows ACS guidelines and age 50 if the state follows United States Preventative
Service Task Force (USPSTF) guidelines. I have researched this information and I am finding
that Tennessee follows ACS guidelines (CRC Screening Law: State of Tennessee, 2019) which
states that we should order colonoscopy on average risk patients at age 45 years old. What we are
finding is that some insurance companies are covering this at 100% as a screening exams and
others are not adhering to this guideline and are applying the charge to the patient’s deductible.
This is very confusing to myself as a provider as I am trying to do what is recommended by my
state and give the best care to my patient without causing them to have financial burdens. I
recently had the opportunity to speak with a physician in Kentucky, Dr. Whitney F. Jones, who
states that they had similar issues and that he had to reach out to a legislator for help. Now the
state of KY follows ACS guidelines as is stated in the state screening laws. I was born in the city
of Cleveland and I want to give the best care of the residents of this community. I realize that I
am a small voice and that I have very little knowledge on health policy and legislation. However,
I do feel that I have a duty to advocate for the patient population that entrust me to their care. I
have always supported you as your constituent. If you have any knowledge or can help in this
area, I would greatly appreciate it.
Respectfully,
Samantha L. Spinks, MSN, AGACNP-BC, CCRN
East Tennessee Gastroenterology
423-339-2000 (work)
423-716-0839 (cell)
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Appendix D
Student Learning Outcomes

Cultural Competence
Cultural sensitivity was observed by understanding that each patient may have diverse
beliefs, values, and strong feelings toward colonoscopy screening and genetic testing. The
United States has a diverse population. Individuals have unique linguistic abilities and ethnic
backgrounds. To provide effective communication literature will was provided verbally,
pictorially, and written at an educational level was appropriate for reading level. Everyone had
the opportunity to express their concerns and answers was provided at a level that they could
understand. The purpose of the procedure was explained to the patient including risk versus
benefits. Certain racial and ethnic diversities were individually addressed to ensure that all
patients received patient centered care to improve the quality of care and reduce the disparity of
colorectal cancer based on evidenced practice.
•

Explanation of procedures was provided verbally and with literature in the preferred
language of the individual.

•

UpToDate database has patient information on colonoscopy in two educational formats
(The Basics is at a 5th grade reading level and Beyond the Basics is above a 5th grade
reading level for patients who have the aptitude skills to comprehend the data)

•

Interactive wallboards in the exam rooms are available for visual demonstration of
colonoscopy screening and colorectal cancer.

•

Literature was provided in the primary language of the patient
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Patient-based approach assessing cross-cultural issues was addressed prior to proceeding
with colonoscopy or genetic screening. Core issues warranting the need for colonoscopy
were explained.

•

Sensitivity to patient’s preference of learning was assessed and respected.

•

Clear communication, focused reassurance, and respect for the patient’s perspective and
concern was done to enhance the therapeutic relationship between that patient and the
nurse practitioner.

Evidence Based Practice:
The purpose of this project was to determine if there is an association between patients who
answer positive to a hereditary cancer screening questionnaire and the premature diagnosis of
colon adenomas. Statistical analysis was performed to determine if the results of the study were
significant. The American Cancer Society, in 2019, reduced the age of colonoscopy screening
from age 50 to 45 on all patients regardless of gender or age based on an increase in the
incidence of colon polyps in patients under the age of 50 years of age (ACS, 2019). Many risk
factors for colorectal cancer have been identified including obesity, history of inflammatory
bowel disease, certain ethic groups, family history of colon cancer, and genetic variants. Genetic
variants that have been associated with the development of colorectal cancer (MLH1; MSH2;
MSH6; PMS2) show a 11% to 47% increase in lifetime risk of developing colon cancer before
the age of seventy years (UpToDate, 2019). Patients who have any of these genetic variants have
a higher risk for developing genetic cancer, some of which have no screening guidelines.
•

Societal Guidelines were observed in formulating a plan of care for patients.

•

Hereditary Cancer Screening questionnaire is a tool to evaluate a family history of
genetically associated cancers.
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If there is an association between patients that have colon adenomas and test positive on a
hereditary cancer screening questionnaire, the questionnaire could be implemented in the
primary care setting to identify at risk patients and refer them for assessment and
evaluation to a Gastroenterology clinic prior to the screening age.

Health Promotion
Colorectal cancer is the third most common cause of cancer diagnosed in the men and
women in the United States (ACS, 2019). Colon cancer can be prevented by colonoscopy and
the removal of adenomatous colon polyps before they progress to an adenocarcinoma. Patients
who have been identified with a genetic variant have an increased lifetime risk of the
development of colon cancer at a younger age. The current screening guidelines vary on state
law and are regulated by the American Cancer Society who has lowered the screening age to 45
years of age. The US Preventive Services Task Force (USPSTF) recommends starting
screenings at age 50. Because colon polyps have no signs or symptoms, patient who develop
symptoms typically have an advanced adenoma or adenocarcinoma. Identification of patients
who are at higher risk for the development of colon cancer based on their genetics would allow
for colonoscopy to be performed at a younger age on a yearly basis to prevent colon cancer. This
would promote health by reducing the disparity of colon cancer by early recognition of at-risk
patients.
Patient Centered Care
Patient centered care incorporates patient concerns with evidenced based practice. The
purpose of this project is to ultimately find a tool that can identify patients who are at an
increased risk for colon cancer and other genetically linked cancers. When genetic variants are
confirmed it allows the patient and the provider to strategize and personalize care.
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Quality and Safety
This project had no safety issues as it is a retrospective correlational study. There were no
safety issues as a result of this project. The project was a correlational study designed to evaluate
a relationship between a history of hereditary cancer syndromes based on a questionnaire that is
filled out by each new patient and the presences of early onset adenomas found on colonoscopy.
The same guidelines and principals set by the American Gastroenterology Association were
adhered to regarding quality and patient safety. After completion of this project the results will
be disseminated.
Informatics and Innovation
Information and innovation were used to collect and analyze data. The electronic medical
record (EMR) that was utilized is called GMED. This EMR was tailored specifically for
gastroenterology practices and imports data collected from colonoscopy, pathology, and chart
notes into one system. The data that were collected and imported into a password protected
excel document to ensure patient privacy. Once enough information was completed to sustain a
reliable g-power the data were imported into SPSS software for analytical analysis.
Teamwork and Collaboration
Teamwork and collaboration were exhibited by having an open line of communication
with my office personal at the University. The project was derived from data that is stored in an
EMR. No assistants helped with input of the data. The original data from the hereditary cancer
screening questionnaire was filled out by the patient, scanned into the chart by the front desk
personnel at the office, and the colonoscopy and pathology report was interfaced into GMED
once the procedure was complete and the pathologist had verified the results. Multiple people
were involved in the project related to their general work roles. The office manager, overseeing
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physician, clinical nurse, fellow colleagues, and faculty advisors were part of the collaborative
effort to make the project a reality.
Professionalism
As healthcare evolves there is a greater need for nurses to reach the highest potential in
their education and career. One day nurses can exhibit this is by improving processes that
impact the care of their patient population. Nurses can have a voice in legislation that will
improve policy and procedures that impact patient care. This project was focused specifically on
another tool to identify patients who are at increased risk for developing adenomatous colon
polyps with an end goal to reduce the prevalence of colorectal cancer. After completion of this
project, and faculty review, this will be submitted to the Society of Gastroenterology Nursing
Association for publication in their journal to educate colleagues on the important findings.
Professionalism is being a leader in one’s area of specialty and advocating not only for patients,
other nurses, but for improved policy and procedures. Use of these research findings as well as
other information obtained as part of the DNP program will augment professional practice in the
role of a doctorally prepared advanced practice nurse.
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Appendix E

The Essentials of Doctoral Education for Advanced Practice Nursing
Essential I. Scientific Underpinnings for Practice
The conceptual framework used for the design of this project as the American
Association of Critical Care Nurses Synergy Model. This model recognizes that synergy is a
unique relationship between nurses and patients (ANCC, 2017). The center of the model
includes the patient’s characteristics and the nurse’s competencies. Surrounding the circle is the
patient, system, and nurse exhibiting how change in function, behavior, resources, and
physiological changes ultimately affect the synergist relationship between the nurse and patient.
The purpose of this scholarly project was to find another tool that will be helpful
identifying patients who are at an increased risk for developing early onset adenomas, factor that
can contribute to the development of early onset colon cancer in genetic variants. Genetic
variants can be tested with DNA testing by saliva or blood or by tissue sample from a cancer.
There are twenty-six genes that have been associated with the development of eight different
cancers. People who carry the genetic variant have a 50% chance of passing the genetic variant
to their children which makes hereditary cancer screening questionnaires relevant in studying if
they are a reliable predictive tool to identify patients who are at risk. In this research, not only
were genetic factors taken into consideration, but age, BMI, and gender were also evaluated. The
goal of this project was making a positive change in gastroenterology which could prevent colon
cancer by early identification.
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Essential II. Organizational and Systems Leadership for Quality Improvement and
Systems Thinking
One of the responsibilities of a doctoral prepared advance practice nurse is to use
leadership skills to reduce healthcare dipartites. Colon cancer is the third leading cause of cancer
in both men and women (ACS, 2018). In 2019, CMS MIPS registry published quality
benchmarks for each specialty of medicine. Measure #185: Colonoscopy Interval for Patients
with a History of Adenomatous Polyps- Avoidance of Inappropriate Use is one that is considered
a high priority measure. The performance measure is based on patients over the age of 18 years
of age having colonoscopy interval of every three years with a personal history of colon
adenomas. Performance measures are not met if the patient undergoes an unnecessary procedure
before three years for adenomas detection rate.
The purpose of this project was to assess if answering positive to a hereditary cancer
screening tool has a statistically significant correlation with patients who are diagnosed with
premature colon adenomas. Patients are offered genetic testing. Those that test positive to
genetic variants would be excluded from QI Measure #185, therefore not affecting reported data.
Individuals who are offered genetic testing and test negative for genetic variants with the
presence of adenomas below the screening age would be subject to American Gastroenterology
Guidelines and would not require unnecessary repeat colonoscopy for three years pending the
prep was adequate, there is no presence of inflammatory bowel disease, and the adenoma was
completely removed (Gastroenterology MIPS Quality Measures and Improvement Activities,
2019).
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Essential III. Clinical Scholarship and Analytical Methods for Evidence-Based Practice
A problem was identified at the research practice site was of concern to the research, the
attention of the primary researcher, the practice manager, and the attending physician. Many of
the patient referrals that were undergoing diagnostic colonoscopy evaluation for rectal bleeding,
abdominal pain, change in bowel habits, constipation, and diarrhea were incidentally found to
have adenomas that had no correlation or relationship to their symptoms. Genetic testing has
been widely available and utilized for breast cancer patients and in oncology after a patient has
been diagnosed with cancer and the tumor has been excised. The capability of genetic testing
exists and can be used as a tool to strategize and individualize patient screening exams. A review
of literature was conducted and analyzed at was found that patients who have genetic variants
develop adenomas at a younger age that have a much faster adenoma to adenoma-carcinoma
carcinoma rate. This project will be analyzed data from the office database and input it into SPSS
for statistical analysis. The findings were disseminated to improve healthcare outcomes in
gastroenterology care.
Essential IV. Information Systems/Technology and Patient Care Technology
Technology and information systems were utilized throughout this project. Initially all
the data was taken from the office EMR, GMED. The data were manually entered a password
protected excel document for patient privacy. Once the data collection was complete the patient
name was replaced with a case number and were entered SPSS for statistical analysis. Upon
completion of the projected the results of the data were presented to assigned faculty advisor in a
word document and power point presentation. Individuals who answer positive to a genetic
screening questionnaire were flagged and genetic testing was discussed and offered.
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Essential V. Health Care Policy for Advocacy in Health Care
At the doctoral level it is expected that nurses engage in politics and have a voice in
policy development. I am a member of the Society of Gastroenterology Nurses Association,
American Critical Care Nurses Association, and the American Nurses Association. Something
that is unique to my field of work is that colonoscopy screenings vary on insurance coverage
based on whether the state recognizes the recommendations by the American Cancer Society or
the U.S. Preventative Services Task Force (USPSTF). The difference is vast. The American
Cancer Society has lowered the overall age of colonoscopy screening to begin at age 45 while
the USPSTF still recommends start at age 50. This is confusing for patients and providers. Based
on my personal research I found that Tennessee was regulated by the American Cancer Society,
and although this is not being publicly reported by insurance companies, they are covering
screenings at age 45 as preventative with 100% coverage.
This is an example of how nurses can make an impact at the legislative level. Knowledge
on state laws is pivotal to patients receiving affordable care. My goal would be that if this project
is successful that I will have the information published in a peer reviewed journal and petition for
legislators to allow genetic testing to be covered as a primary preventative strategy under all
health care plans.
Essential VII. Clinical Prevention and Population Health for Improving the Nation’s
Health
The goal of this project is to reduce the health disparities related to colorectal cancer by
identifying if a hereditary cancer screening questionnaire is a viable took to recognize patients
who may have early onset adenomas. If so, this would decrease the mortality rate of colorectal
cancer as polyps would be removed from patients who are at increased risk. In the least, patients
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who are shown to be at risk will be given the option for genetic testing to confirm that they have
or do not have a genetic variant putting them at a much greater risk for the early development of
colon cancer. Certain ethnicities are at risk for colorectal cancer at an early age such as African
American. Being male, being over the age of 50 years old, smoking, obesity, and a diet high in
red meat are all risk factors. While risk factors pose a threat, genetic variants most certainly carry
more weight when it comes to the probability of someone developing a cancer. Therefore, this
project can potentially affect population health, as it can give us another tool to find those
patients who are asymptomatic but are at increased risk due to their family history of genetically
inherited cancers
Essential VII. Advanced Nursing Practice
My doctorate is focused on Acute Care Specialization. I see primarily patents who have
GI disorders in clinic and in the hospital setting. One of the most despairing news to tell a patient
is that they have cancer. Particularly with patients who are young and would never be on the
radar for cancer screening modalities. Pancreatic cancer, until this year, had no formal cancer
screening protocols. Thanks to M.D. Anderson we now have a framework that we can utilize to
screen people for pancreatic cancer based on their family history. This is the same for colorectal
cancer screening. As APN’s it is our duty to advocate, educate, and facilitate optimal care to
ensure good patient outcomes. Conceptual and analytical skills will be used to provide
statistically significant information substantiating the need to screen all individuals who may be
at risk for the early development of hereditary cancers. As a nurse practitioner, it is my duty to
guide my patients and provide them with the most up to date information so that as a team we
can make decisions on their care together. As a DNP, I have an obligation to disseminate my
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Appendix F

Data showing trends in Colorectal Cancer Incidence Rates by Age and Year of Birth, and
by Age and Year of Diagnosis, United States, 1975 to 2014. Data Source Surveillance,
Epidemiology, and End Results (SEER) program, National Cancer Institute
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Trends in Colorectal Cancer Incidence Rates by Age (Ages 20-49) and Ages 50+) and Sex,
1975 to 2014. Rates are adjusted for delays in reporting and are plotted as a 2-year moving
average. Data source: Surveillance, Epidemiology, and End Results Program, National
Cancer Institute.
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Appendix G
Statistical Charts
BMI
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